Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DETLAH???
Well Oncolix listed him as an advisor on their website eventhough, technically, he no longer was. He didn't have a problem with it until he started getting pestered by people from the Oncolix ihub board. Once that happened, he wrote a letter to Oncolix asking them to take his name off their site.
At the end or the day, Chens involvement has no bearing on the outcome of Prolanta's success. He can't do anything special to effect the trials and as we know, Oncolix doesn't have any money to pay for his help either. If it goes to market, he banks, if it doesn't, he still made money up front.
IMO
He walked away from Prolanta like he did Somavert. With Somavert, Pfizer stepped in and purchased the rights to develop and test the drug in clinical trials. Wen Chen and Ohio State get paid millions per year in royalties from their licensing agreement with Pfizer. Chen basically invents a drug, finds a pharmaceutical company willing to pay a sum up front to develop it, and he moves on to research something new. If one of his inventions hits the market, he cashes in big time like he has with Somavert.
He's so well off right now that whatever happens with Prolanta's success is of little concern to him.
IMO
Feb 2019
WHY WOULD THEY DO THAT??? LET THE FREAKIN STOCK TRADE ON THE WEEKEND. SOMETHING FISHY IS GOING ON HERE!!!
Oncolix is +40% since mid October!!! And big things on the horizon with Prolanta and Cyclosam!!!
I wish they would stop halting this. How is the price ever gonna go up if they keep doing that?
Seems like MMs are doing to dumping AKA dilution.
This is gonna go big time. Most legit reverse merger ever.
Check out NHPI. Massive reverse merger with Woodbrook Group which is one of the fastest growing foreign investment companies. Back in June or July they merged with a company called Felicitas that is managing over $198m in assets. Current price is .0041 and the shell is clean clean clean.
Check out NHPI. Massive reverse merger with Woodbrook Group which is one of the fastest growing foreign investment companies. Back in June or July they merged with a company called Felicitas that is managing over $198m in assets. Current price is .0041 and the shell is clean clean clean.
Hey you need to check out NHPI reverse merger with Woodbrook Group. The DD on Woodbrook Group is unlike anything I've ever seen. Back in 2016 they were talking about doing a Nasdaq IPO but have now chosen NHPI as their vehicle for going public. They just recently merged with a company back in the summer called Felicitas. Felicitas manages $198m+ in assets. This might be one of those stocks you dont want to miss out on.
Reverse Werger
HALTTTTTT!!!!!!!!!!!!
What's the connection between MSMY and MGON?
Once the shell is transferred to the new owner, Adam Tracy or whoever else no longer matters anymore.
Why do you hate shells so much? You don't think it's possible for a legitimate company to use a shell to go public?
NONE BECAUSE THEY HALTED MY PRESCRIPTION :(
ITS BECAUSE ITS HALTED!!! ONLY REASONABLE EXPLANATION!!!
IMO
WHY DID THEY HALT IT??? HOW DO I GET MY SHARES OUT??? DOES FINRA HAVE THEM???
OMG NO WAY!!! THIS IS TERRIBLE NEWS!!! HOW MANY MORE MILLIONS OF SHARES NEED TO TRADE TO GET UNHALTED???
DUDE DID YOU CHECK WITH FINRA TODAY TO SEE IF FLTT WAS HALTED?
No doubt that Bon-Ton has value. The question is whether the BONTQ shares have any value? Is Bon-Ton still considered a public company? Will they have to issue new shares under a different ticker once they emerge from bankruptcy?
If somehow the BONTQ shares are still tied to the company, then this is going to be a goldmine. But these shares could actually be worthless like the majority of the 'Q' tickers.
So Bon-Ton was auctioned off to liquidators and closed all of its stores last week. A new company has come in called CSG Generation and is working with the liquidators to buy the Bon-Ton brands and reopen the stores. They are just waiting on an approval from then bankruptcy court.
Anyone have any idea what this means for the commons?
https://www.jsonline.com/story/money/business/2018/09/06/indiana-company-attempt-revive-bon-ton-stores/1206388002/
I'll start off by saying I dont know a ton of the DD behind this merger, so I'm hoping someone can help me. Anyone know what's up with the SS and all of those restricted shares? I noticed the AS is essentially maxed out. Has anyone involved in the merger addressed this? Have the shares from Green Zebra already been accounted for? I only ask, because I've been involved with a few mergers where they drop the filings and some unfavorable language is included in their contents.
Sounds about right.
Something big could be happening here. One address is for Schlumberger Tech Corp and huge oil co. Another address is for a repair serivices company in Philadelphia. The Newtown PA address leads to a huge mansion. Then the Pottsville address is either for another house or coal/concrete business. And then the West Hollywood address leads to an apartment complex called the Ro-Mi Palms.
Oh wait Schlumberger Tech Corp is a private company. Apparently they did $30b in revenue in 2017.
If that's what's merging in, see you at $50 pps.
Yep you're right. So it must be some other company merging or it's something completely different.
They go from private to public...
Attorney Letter out
They also stated that they have agreements with a manufacturer for Prolanta. An agreement is a contract and a contract is an agreement and a contract manufacturer is a manufacturer that works via contract and when you have an agreement with a contract manufacturer you also have a contract with the contract manufacturer.
IMO
If you read carefully, you can see that Oncolix has incurred contract manufacturing costs. So there was cash exchanged for the services of a contract manufacturer. I would say that not only have they "engaged" a contract manufacturer, but they are most certainly doing "business" with a contract manufacturer.
IMO
From the 10-Q:
"We have engaged a contract manufacturer to develop methods of production of Prolanta and to produce quantities necessary for our animal and human testing. Accordingly, our operations are dependent upon the manufacturer’s ability to manufacture suitable quantities of Prolanta in compliance with regulatory requirements and within acceptable timeframes, and to maintain regulatory licenses for its operations. Failure to maintain such regulatory requirements would have a material impact on our operations. We incurred contract manufacturing costs of $9,925 and $0 during the three months ended June 30, 2018 and 2017, respectively, and $9,925 and $3,476 during the six months ended June 30, 2018 and 2017, respectively."
"In early 2016, we commenced a Phase I clinical trial of Prolanta for the treatment of ovarian cancer. This trial will evaluate three dose-levels of Prolanta according to a protocol submitted to the FDA. We completed the first dosing group in June 2016, and our Data and Safety Monitoring Board (“DSMB”) has given us permission to dose a second group of patients with a higher dose of Prolanta. Solicitation of enrollment of this second group has commenced."
"Our agreements with both the manufacturer of our drug Prolanta and the organizations that will provide monitoring and regulatory services for our clinical trials provide that our capital stock was issued for part of the value of the total services rendered. The original value of the stock issued was recorded as a prepayment of future services and is expensed as the services are rendered. The remaining balance is reflected as prepaid services in the accompanying condensed balance sheets."
"As of June 30, 2018, an affiliate of GHS holds approximately 40% of the voting interest in Oncolix. An affiliate of GHS is the site for clinical trial activities. Accounts payable to GHS and its affiliates for services were approximately $61,935 at June 30, 2018 and December 31, 2017, respectively.
We have engaged a contract manufacturer and clinical research firms and certain of the costs incurred have been paid or will be paid through the issuance of capital stock. See Note 3."
"Research and development expense increased approximately $37,000 from the three months ended June 30, 2017 to the comparable period in 2018, principally as a result of process development and consulting costs incurred in 2018 as the Company evaluated improvements to its manufacturing process. The Company commenced enrollment of the second dosing group in its Phase I clinical trial during 2018, but no significant costs have been incurred as of June 30, 2018."
Looks like things are actually moving along here.
Article published August 3rd 2018...
I keep finding studies that are recent in regards to Prolanta (G129R). This article was published August 3rd 2018. Does this mean that Prolanta is being actively studied and tested?
http://beatingcancercenter.com/2012-11-24-22-19-50/related-researches/2000-2009/2379-additive-effects-of-a-prolactin-receptor-antagonist-g129r-and-herceptin-on-inhibition-of-her2-overexpressing-breast-cancer-cells.html
It is August and the insiders will soon be able to capitalize on their investment. It would make sense for them to delay their news catalysts until now. I wouldn't be surprised to see something in regards to the trials released very soon.
IMO
Someone should call the number in that link to verify the PR.
If news is real it's probably an insider. This might be the beginning of a nice pump.
Can you screenshot that or link it?